---
title: "傑富瑞將鉅子生物的目標價從 55 港元下調至 50 港元，維持買入評級"
description: "傑富瑞將鉅子生物的目標價從 55 港元下調至 50 港元，維持買入評級"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273680301.md"
published_at: "2026-01-26T09:34:13.000Z"
---

# 傑富瑞將鉅子生物的目標價從 55 港元下調至 50 港元，維持買入評級

### Related Stocks

- [588250.CN - 鵬華上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [159859.CN - 天弘國證生物醫藥ETF](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [02367.HK - 鉅子生物](https://longbridge.com/zh-HK/quote/02367.HK.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [159102.CN - 華安恆生生物科技ETF](https://longbridge.com/zh-HK/quote/159102.CN.md)
- [513120.CN - 廣發中證香港創新藥(QDII-ETF)](https://longbridge.com/zh-HK/quote/513120.CN.md)
- [513700.CN - 香港醫藥](https://longbridge.com/zh-HK/quote/513700.CN.md)
- [520690.CN - 博時恆生港股通創新藥精選ETF](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [159316.CN - 易方達恆生港股通創新藥ETF](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [516500.CN - 華夏中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/516500.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| Elon Musk’s Neuralink sparks BCI race in China | Neuralink, founded by Elon Musk, is driving a surge in brain-computer interface (BCI) development in China, with startup | [Link](https://longbridge.com/zh-HK/news/276460367.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
